Plaintiff
5 cases as plaintiff.
Halozyme Inc., also known as Halozyme Therapeutics, Inc. (NASDAQ: HALO), is a publicly traded American biotechnology company headquartered in San Diego, California. Founded in 1998, Halozyme focuses on developing and commercializing drug delivery technologies. As of December 31, 2025, the company had 423 employees and reported a trailing twelve-month revenue of $1.397 billion. Its market capitalization was approximately $8.41 billion as of May 12, 2026.
Halozyme's primary business revolves around its proprietary ENHANZE® drug delivery technology. This platform utilizes a recombinant human hyaluronidase enzyme, rHuPH20, to facilitate the subcutaneous delivery of injectable biologics that traditionally require intravenous administration. This technology aims to improve patient convenience and adherence by reducing administration time and injection volume. Halozyme licenses its ENHANZE® technology to leading pharmaceutical companies, generating significant royalty revenue from commercialized products. The company also has its own proprietary commercial products, including Hylenex® and XYOSTED®.
Halozyme's patent litigation posture indicates it is an operating company that defends its intellectual property. The company has one tracked case in our database, appearing as a defendant in "Unified Patents v. Halozyme Inc" before the Patent Trial and Appeal Board (PTAB). This suggests that Halozyme is primarily focused on developing and commercializing its technologies and defending its patents when challenged, rather than asserting them as a plaintiff.
Notable collaborations include licensing agreements for its ENHANZE® technology with major pharmaceutical and biotechnology companies such as Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, and GSK. These partnerships have led to the commercialization of numerous ENHANZE®-enabled products across various therapeutic areas, including oncology. Recent developments include collaborations with Vertex Pharmaceuticals for its Hypercon™ technology and with Oruka Therapeutics, Inc.
Watchlist
Email-only, free, anonymous. We'll notify you when Halozyme, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Halozyme, Inc. sued Merck Sharp & Dohme Corp. (now Merck Sharp and Dohme LLC), alleging that Merck's subcutaneous KEYTRUDA® formulation infringes 15 of Halozyme's patents, including US 11041149. Halozyme seeks damages and injunctive relief to block commercialization of SC Keytruda, also alleging willful infringement.
Halozyme, Inc. filed an infringement action against Merck Sharp & Dohme Corp., with Merck Sharp and Dohme LLC later substituted as the defendant. The case is pending, and Merck Sharp and Dohme LLC was granted time to respond to the complaint.
Halozyme sued Merck for patent infringement over Merck's subcutaneous Keytruda (SC KEYTRUDA, berahyaluronidase alfa), asserting 15 patents including the '520 patent and seeking damages and an injunction. The case is pending in the District of New Jersey and was later reported as administratively stayed pending PTAB and appellate proceedings.
Patent infringement and declaratory judgment action filed by Halozyme against Merck in the District of New Jersey asserting 15 Halozyme MDASE platform patents, including US 12,049,652, over subcutaneous pembrolizumab (Keytruda Qlex/Keytruda SC). The case remains pending and the '652 patent remains at issue.
Halozyme filed a patent infringement and declaratory judgment action against Merck in the District of New Jersey. The '692 patent is one of 15 patents-in-suit asserted against Merck's subcutaneous Keytruda, appearing as Count 10. The case remains pending, with the complaint and Merck's answer as the primary substantive filings.